Cellceutix Corp. has signed an agreement with a EU clinical site for a Proof-of-Concept (PoC) trial of Prurisol, the company’s lead drug candidate for the treatment of psoriasis. The trial, a double-blind study, is planned for 1Q13 and will include patient dosing over a 30-day period with follow up visits over the next 30 days.   “Our lab research showed Prurisol to visually eliminate all traces of psoriatic tissue in human xenograft models in a short period of time. We are very optimistic that ...